MECHLORETHAMINE (MUSTARGEN)

Course overview

Mechlorethamine is U.S. FDA-approved as palliative treatment for chronic lymphoid leukemia (CLL), chronic myeloid leukemia (CML), stage III/IV Hodgkin disease, lymphosarcoma, malignant effusion secondary to metastatic carcinoma, mycosis fungoides (I.V. only), polycythemia vera, and bronchogenic squamous cell carcinoma. This continuing education module is designed to give the reader/learner an increased understanding of mechlorethamine. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.